Compare Cytokinetics Inc (CYTK) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Li Auto Inc — how do they compare? Cytokinetics Inc trades at $62.1 (market cap $8.62B), while Li Auto Inc trades at $11.4 (market cap $10.71B). The key difference: Li Auto Inc is the larger of the two by market cap, and Cytokinetics Inc is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Li Auto Inc for 101 Days on average.
| CYTK | LI | |
|---|---|---|
Market Cap | $8.62B | $10.71B |
Volume | 2,594,626 | 1,781,143 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $23.61 |
52-Week Low | $54.76 | $10.69 |
Typical Hold Time | 19 Days | 101 Days |
Enterprise Value | $8.72B | $139.58M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Li Auto (LI) trades at $10.99, near its 52-week low, with a bearish technical signal and recent earnings misses in Q1 and Q2 2026. Revenue declined to $112.31B in 2025, with a net income margin of 1%, while cash flow from operations turned negative. The company faces intense competition in China's EV market, though new model launches like the Li i9 aim to revive growth.
The stock presents a high-risk opportunity, with a consensus price target of $15.18 implying upside, but investors must weigh analyst caution (43.75% buy rating) against execution risks and ongoing cash burn. Near-term performance hinges on delivery recovery and margin improvement amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
